Moderna (MRNA) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Leadership and organizational evolution

• Expanded leadership role now covers full product lifecycle, including commercial operations.

• Transitioning focus from pandemic response to building robust commercial capabilities.

• Strategic leadership changes allow CEO to focus on broader company responsibilities.

Commercial strategy and market outlook

• Targeting $3–$3.5 billion in commercial revenue this year, mainly from Spikevax.

• Rapidly building marketing and sales capabilities, focusing on a few key markets.

• Planning up to 10 product launches over the next three years, including oncology and rare diseases.

• COVID vaccination market is stabilizing, with retail channels showing resilience.

• Non-retail channels present growth opportunities, especially in integrated delivery networks.

Public health and regulatory environment

• Vaccines remain a cost-effective public health intervention, saving health systems money.

• Ongoing collaboration with governments and public health officials, regardless of administration changes.

• High confidence in regulatory science and advisory processes guiding vaccine approvals.

• Pipeline includes products for cancer and rare diseases, with tailored regulatory strategies.